Shandong Buchang Pharmaceuticals (603858) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

CN Stock MarketDetailed Quotes

603858 Shandong Buchang Pharmaceuticals

Watchlist

15.31
-0.05-0.33%

Market Closed Jan 15 15:00 CST

16.93BMarket Cap-57.77P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Buchang Pharma's Unit Gets Approval to Market Oseltamivir Phosphate Dry Suspension
MT NewswiresJan 9 23:16 ET
Buchang Pharmaceuticals to Set Up Medical Equipment Subsidiary
MT NewswiresJan 9 00:30 ET
Shandong Buchang Pharmaceuticals Terminates Agreements With Nantong Lianya Pharmaceutical
MT NewswiresDec 26, 2024 23:03 ET
Does Shandong Buchang Pharmaceuticals (SHSE:603858) Have A Healthy Balance Sheet?
Simply Wall StDec 19, 2024 20:16 ET
Buchang Pharmaceuticals Gets Drug Registration for Donepezil Hydrochloride Tablets
MT NewswiresDec 4, 2024 00:29 ET
Shandong Buchang Pharmaceuticals Passes GMP Compliance for Meihekou, China Production Line
MT NewswiresDec 2, 2024 00:53 ET

Comments

Moomoo AI

Feb 24, 2024 19:30

Shandong Buchang Pharmaceuticals' share price and EPS decline over the past three years hint at ongoing challenges. The company's underperformance compared to the broader market over the past year may suggest unresolved issues. Investors should consider market conditions and other key factors.

Shandong Buchang Pharmaceuticals (SHSE:603858) Shareholders Have Endured a 15% Loss From Investing in the Stock Three Years Ago

Moomoo AI

Jan 8, 2024 17:57

Shandong Buchang Pharmaceuticals' low P/S ratio may reflect expectations of continued disappointing revenue performance. The company's declining revenue and predicted industry growth could challenge its current P/S ratio, potentially disappointing shareholders. Current investor sentiment and future expectations do not seem to justify a higher P/S ratio for the company.

Investors Don't See Light At End Of Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Tunnel

Moomoo AI

Nov 1, 2023 17:55

The recent sell-off could be an opportunity, but it's recommended to check the fundamental data for signs of a long-term growth trend. There are also 2 warning signs for the company that should be considered.